Molecular analyses on the intercellular signaling relating to the bone destruction of ameloblastoma
Molecular analyses on the intercellular signaling relating to the bone destruction of ameloblastoma
批准号:
23592929
负责人:
NAKAMURA Norifumi
金额:
$3.33万
依托单位:
依托单位国家:
日本
项目类别:
Grant-in-Aid for Scientific Research (C)
财政年份:
2011
资助国家:
日本
项目状态:
已结题
起止时间:
2011 至 2013
中文摘要
建立了来自口腔粘膜的永生化上皮细胞系(MOE-1)作为对照,以及来自滤泡型成釉细胞瘤的永生化成釉细胞瘤细胞系(AM-3),并将其生物学特性与AM-1(先前建立的来自预成形型成釉细胞瘤的永生化成釉细胞瘤细胞)进行了比较。AM-1和AM-3对上皮标记物呈阳性反应,对间质标记物呈阴性反应,维持上皮细胞的形态特征。MMP-2和MMP-9在AM-1和AM-3中的表达明显高于MOE-1。AM-1和AM-3的Wnt-5a及Wnt信号受体LRP和Frizzled mRNA水平均高于MOE-1。此外,在Wnt-3a蛋白刺激下,AM-3中MMP-9的表达和活性呈剂量和时间依赖性增加。这些结果提示,MMPs的表达可能通过Wnt信号通路调控成釉细胞瘤的局部侵袭性。
英文摘要
Immortalized epithelial cell line derived from oral mucosa (MOE-1), as control, and immortalized ameloblastoma cell line derived from follicular-type ameloblastoma (AM-3) were established and their biological characteristics were compared to AM-1, previously established immortalized ameloblastoma cells derived from prexiform-type ameloblastoma.AM-1 and AM-3 demonstrated positive reaction to the epithelial markers and negative to the mesenchymal one maintaining the morphological characteristics of the epithelial cell. Expressions of MMP-2 and MMP-9 were significantly higher in AM-1 and AM-3 than MOE-1. Wnt-5a and Wnt signaling receptors, LRP and Frizzled, of both AM-1 and AM-3 were higher than MOE-1 in the mRNA level. Furthermore, expression and activity of MMP-9 in AM-3 increased dose- and time-dependently when stimulated with Wnt-3a protein.These results suggested that local invasiveness of ameloblastoma may be regulated by MMPs expression through the Wnt signaling pathway.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
登录
查看更多内容
新規口腔粘膜上皮細胞株M0E1の樹立-HPVやSV40を用いない不死化-
新型口腔粘膜上皮细胞系 M0E1 的建立 - 不使用 HPV 或 SV40 的永生化 -
DOI:
--
发表时间:
2011
期刊:
影响因子:
--
作者:
[岐部俊郎, 比地岡浩志, 宮脇昭彦, 中村典史, 岸田昭世]
通讯作者:
岸田昭世
The role of Wnt signaling pathway in growth characteristics of Ameloblastoma cells.
Wnt信号通路在成釉细胞瘤细胞生长特性中的作用。
DOI:
--
发表时间:
2011
期刊:
影响因子:
--
作者:
[Toshiro Kibe, Shosei Kishida, Hiroshi Hijioka, Akihiko Miyawaki, Norifumi Nakamura]
通讯作者:
Norifumi Nakamura
Establishment of novel ameloblastoma-derived cell line, and the role of Wnt signaling pathway in ameloblastoma.
新型成釉细胞瘤细胞系的建立及Wnt信号通路在成釉细胞瘤中的作用。
DOI:
--
发表时间:
2013
期刊:
Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology & Endodontics
影响因子:
--
作者:
[Toshiro Kibe, Takao Fuchigami, Michiko Kishida, Mikio Iijima, Hiroshi Hijioka, Akihiko Miyawaki, Ichiro Senba, tooru Kiyono, Norifumi Nakamura, Shosei Kisida]
通讯作者:
Shosei Kisida
新規口腔粘膜上皮細胞株MOE1の樹立 -HPVやSV40遺伝子を用いない不死化-
新型口腔粘膜上皮细胞系MOE1的建立 - 不使用HPV或SV40基因的永生化 -
DOI:
--
发表时间:
2011
期刊:
影响因子:
--
作者:
[Toshiro Kibe, Shosei Kishida, Hiroshi Hijioka, Akihiko Miyawaki, Norifumi Nakamura, 岐部俊郎,比地岡浩志,宮脇昭彦,中村典史,岸田昭世]
通讯作者:
岐部俊郎,比地岡浩志,宮脇昭彦,中村典史,岸田昭世
Immortalization and characterization of MOE1 cells, normal oral epithelial cell lines without using HPV and SV40 genes-.
MOE1 细胞、正常口腔上皮细胞系的永生化和表征,无需使用 HPV 和 SV40 基因。
DOI:
--
发表时间:
2011
期刊:
Oral Science International
影响因子:
0.5
作者:
[Toshiro Kibe, Michiko Kidhida, Masayuki Kaimo,Mikiko Iiima, Lin Clen. Mika Habu, Akihiko, Miyawaki, Hiroshi Hijioka, Norifumi Nakamura, Tohru Kiyono, Shosei Kishida]
通讯作者:
Shosei Kishida
共 14 条
Development of the cleft palate speech assessment and treatment system using a new neural network theory
-
批准号:17H04407
-
项目类别:Grant-in-Aid for Scientific Research (B)
-
资助金额:$6.99万
-
财政年份:2017
-
负责人:NAKAMURA Norifumi
-
依托单位:
Epithelial and mesenchymal cross-talk on mechanism of bone invasion of ameloblastoma
-
批准号:26463019
-
项目类别:Grant-in-Aid for Scientific Research (C)
-
资助金额:$3.08万
-
财政年份:2014
-
负责人:NAKAMURA Norifumi
-
依托单位:
Identification of the susceptibility genes for nonsyndromic cleft lip and /or palate
-
批准号:16390594
-
项目类别:Grant-in-Aid for Scientific Research (B)
-
资助金额:$8.64万
-
财政年份:2004
-
负责人:NAKAMURA Norifumi
-
依托单位:
Study on development, proliferation and differentiation of ameloblastoma
-
批准号:04454507
-
项目类别:Grant-in-Aid for General Scientific Research (B)
-
资助金额:$4.29万
-
财政年份:1992
-
负责人:NAKAMURA Norifumi
-
依托单位:
海外基金